CHPI E-news mid summer research update:.

RT @CHPI1: Opinion: National pharmacare will reduce drug access for almost 26 million Canadians 

Opinion: National pharmacare will reduce drug access for almost 26 million Canadians 

National pharmacare will reduce access to new medicines for 27 million privately insured Canadians

Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients

Opinion: Controlling drug costs doesn't require pharmacare

Cost control rationale for pharmacare does not stand up to scrutiny: Canadian Health Policy Institute.

National pharmacare is not necessary. It will be bad for patient access and costly for taxpayers. In this Toronto Star opinion CHPI CEO Brett Skinner identifies several inconvenient facts, ignored by pharmacare advocates:.- People in the lowest income deciles who fall in the gaps.

Dr. Nigel Rawson in the Hill Times: The Patented Medicine Prices Review Board (PMPRB) has demonstrated such dysfunction and bias it should be disbanded.

NEW STUDY - Evaluation of the PMPRB regulatory performance on price review for new patented drugs in Canada, 2008-2021. Nigel SB Rawson, PhD and Brett J Skinner, PhD. #healthpolicy #cdnpoli

CHPI's Yanick Labrie co-authored a new study suggesting that Quebec could save over $7 million annually if patients with HER2+ breast cancer received subcutaneous administration of Herceptin® at local community service centres (CLSCs) rather than receiving it intravenously in

RT @CHPI1: Cancer is the leading cause of death in Canada, but public drug plans cover only 11% of new cancer drugs, Canadians wait 1,835 d….

RT @CHPI1: New study: Economic burden of cardiomyopathy $5 billion/yr. Patented drugs account for less than 1%. As first line therapy pharm….

Cancer is the leading cause of death in Canada, but public drug plans cover only 11% of new cancer drugs, Canadians wait 1,835 days for coverage, and sales of new cancer drugs are only 1.3% of national health expenditure: new study. #cdnpoli #cdnecon

New study: Economic burden of cardiomyopathy $5 billion/yr. Patented drugs account for less than 1%. As first line therapy pharmaceutical innovation offers opportunity to avoid downstream hospital cost, productivity loss, mortality. #cdnhealth #cdnpoli

"the Patented Medicine Prices Review Board – Canada’s federal drug-price regulating agency – has sought to impose lower drug costs when new pharmaceuticals are introduced here. But the main achievement of that crusade is that fewer new medicines are now

Is it time to retire the patented medicines price regulator? Recommended read from CHPI's Nigel Rawson and John Adams in the Financial Post: #pmprb #cdnhealth #cdnpoli.

Read the latest article from CHPI's Nigel Rawson and John Adams. Opinion: For drug access, Canadians with rare disorders are 40 years behind Americans #Pharmaceutical #Health #Canada #PMPRB.

RT @CHPI1: Study finds federal changes to patented medicines regulations linked to fewer new drugs in Canada versus the United States and E….

Study finds federal changes to patented medicines regulations linked to fewer new drugs in Canada versus the United States and Europe. #Pharmaceutical #health #Canada.